In an April 4 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Inovio Pharmaceuticals Inc.'s (INO:NASDAQ) immunotherapeutic agent, INO-3106, showed efficacy against the human papilloma virus (HPV) type 6 in the pilot study of two patients with recurrent respiratory papillomatosis (RRP), a rare disease that causes noncancerous tumor growth.
Whereas before the study the two patients required surgery every six months to remove the tumors, after receiving the fourth and final INO-3106 dose, they have not needed surgical intervention, one for as long as two years, one for more than a year.
"The positive data enable the company to expand its pipeline of candidates targeting HPV-related diseases, including VGX-3100 for cervical dysplasia and MEDI0457 for head and neck cancer, and represents a step forward toward the company's goal of treating all HPV-related precancers and cancers," Selvaraju commented.
Inovio intends to advance INO-3106 for the treatment of RRP in the pediatric and adult populations.
In other news, enrollment in Inovio's Phase 3 REVEAL 1 study of VGX-3100 for the treatment of cervical dysplasia is nearly done. Later this year, interim results are expected for the two Phase 2 trials evaluating this same immunotherapy in HPV-related vulvar and anal dysplasia in the U.S.
Also expected this year are data from Medimmune on MEDI0457 (previously INO-3112)in metastatic HPV-associated head-and-neck squamous cell cancer.
H.C. Wainwright & Co. has a Buy rating and a $13 per share target price on Inovio, whose stock is currently trading at around $4.02 per share.
[NLINSERT]Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures from H.C. Wainwright & Co., Inovio Pharmaceuticals Inc., Company Update, April 4, 2019
Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.
I, Raghuram Selvaraju, Ph.D. and Yi Chen, Ph.D. CFA, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.
None of the research analysts or the research analyst's household has a financial interest in the securities of Inovio Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position).
As of March 31, 2019 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Inovio Pharmaceuticals, Inc.
Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.
The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.
The Firm or its affiliates did receive compensation from Inovio Pharmaceuticals, Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.
H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Inovio Pharmaceuticals, Inc. during the past 12 months.
The Firm does not make a market in Inovio Pharmaceuticals, Inc. as of the date of this research report.
